INZY — Inozyme Pharma Cashflow Statement
0.000.00%
Last trade - 00:00
- $274.27m
- $130.45m
- 44
- 24
- 72
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -19.7 | -56.4 | -56.6 | -67.1 | -71.2 |
Depreciation | |||||
Non-Cash Items | 0.23 | 20.3 | 7.71 | 6.54 | 2.74 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.601 | -0.111 | 0.085 | 2.01 | -3.08 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -18.8 | -36 | -48.2 | -57.8 | -70.7 |
Capital Expenditures | -0.139 | -0.568 | -0.397 | -0.41 | -0.298 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -8.25 | -117 | 43.2 | -4.99 | -53.3 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -8.39 | -117 | 42.8 | -5.4 | -53.6 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 23 | 150 | 0.609 | 72.8 | 126 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -4.23 | -3.34 | -4.72 | 9.6 | 1.63 |